Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial symbols : FNCTF save search
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
FNCTF | News | $11.16 130
|
Communications
|
| O: -100.0%
H: NaN%
C: Infinity%
GILD | $67.25 0.45% 2M
|
Health Technology
|
| O: 0.5%
H: 0.83%
C: 0.28%
CTXR | $0.7697 4.84% 380K
|
Health Technology
|
| O: 2.33%
H: 2.28%
C: -4.23%
hope treatment pharmaceuticals city for car-t trial
GammaTile® Marks Milestone: 100th Patient Enrolled in Groundbreaking ROADS Phase 3 Clinical Trial for Newly Diagnosed Metastatic Brain Tumors
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
FNCTF | News | $11.16 130
|
Communications
|
| O: 0.17%
H: 0.0%
C: -0.43%
gammatile tumors for trial
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
Published: 2024-03-21 (Crawled : 12:00) - biospace.com/
MRK | $126.99 0.04% 3.1M
|
Health Technology
|
| O: -0.13%
H: 0.4%
C: -0.06%
ylynk-006 keytruda lung merck update cancer cell trial plus
City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial
Published: 2024-03-07 (Crawled : 12:30) - biospace.com/
FNCTF | News | $11.16 130
|
Communications
|
| O: 0.79%
H: 0.78%
C: 0.78%
MBIO | $0.365 7.35% 48K
|
Health Technology
|
| O: 8.33%
H: 4.2%
C: -2.8%
FBIO | $1.78 1.71% 74K
|
Health Technology
|
| O: 2.93%
H: 0.0%
C: -9.21%
tumors cell city trial therapy
City of Hope presents pivotal clinical trial data at American Society of Hematology (ASH) conference on revumenib, a potential new targeted therapy for high-risk subtypes of acute leukemias
Published: 2023-12-12 (Crawled : 21:00) - biospace.com/
FNCTF | News | $11.16 130
|
Communications
|
| O: -0.07%
H: 1.35%
C: -0.1%
conference hope city trial potential therapy
Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LYNPARZA® (olaparib) for Patients With Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility
Published: 2023-12-07 (Crawled : 18:00) - biospace.com/
MRK | $126.99 0.04% 3.1M
|
Health Technology
|
| O: -0.04%
H: 0.01%
C: -1.61%
ylynk-008 keytruda lung merck cancer cell trial plus
Nokia and Orange set record with 800Gbps transmission trial on 6,600km Dunant live network to prepare for soaring traffic on strategic trans-Atlantic route
Published: 2023-12-06 (Crawled : 08:00) - globenewswire.com
FNCTF | News | $11.16 130
|
Communications
| Email alert
Add to watchlist
set network trial
BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results
Published: 2023-11-14 (Crawled : 12:00) - globenewswire.com
BTAI | News | $3.005 5.44% 240K
|
Health Technology
|
| O: -35.39%
H: 19.38%
C: 18.54%
fda update trial therapeutics financial results
Viking Therapeutics to Highlight Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023
Published: 2023-10-10 (Crawled : 20:00) - prnewswire.com
VKTX | $67.33 5.45% 1.1M
|
Health Technology
|
| O: 1.32%
H: 1.48%
C: -5.13%
LGND | $70.655 3.1% 61K
|
Health Technology
|
| O: -0.58%
H: 0.0%
C: -1.88%
vk2735 obesityweek agonist presentation trial therapeutics
Inland Empire Trial Lawyer William D. Shapiro Elected National Vice President of the American Board of Trial Advocates (ABOTA)
Published: 2023-10-06 (Crawled : 20:00) - prnewswire.com
FNCTF | News | $11.16 130
|
Communications
| Email alert
Add to watchlist
trial
City of Hope Opens First U.S. Multicenter Clinical Trial for Robotic Single-Port Mastectomies for Breast Cancer Patients
Published: 2023-10-03 (Crawled : 16:00) - biospace.com/
FNCTF | News | $11.16 130
|
Communications
| Email alert
Add to watchlist
breast hope cancer city trial
Calidi Biotherapeutics and City of Hope Announce First Patient Dosed in a Phase 1 Clinical Trial Evaluating Neural Stem Cells Engineered to Carry an Oncolytic Virus, CLD-101, in Recurrent High-grade Glioma Patients
Published: 2023-07-18 (Crawled : 14:00) - biospace.com/
FNCTF | News | $11.16 130
|
Communications
| Email alert
Add to watchlist
cld-101 hope city trial
Lyndra Therapeutics Announces Leadership Changes, Update on Pivotal Trial Progress
Published: 2023-07-17 (Crawled : 13:20) - biospace.com/
FNCTF | News | $11.16 130
|
Communications
|
| O: 4.62%
H: 0.0%
C: -1.54%
GILD | $67.25 0.45% 2M
|
Health Technology
|
| O: -0.67%
H: 1.42%
C: 1.06%
update trial therapeutics
Antibody-drug Conjugates Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain
Published: 2023-06-26 (Crawled : 21:00) - prnewswire.com
LLY | News | $741.37 1.37% 800K
|
Health Technology
|
| O: 2.15%
H: 1.18%
C: 0.43%
SRNE | $0.015 140K
|
Health Technology
|
| O: -1.0%
H: 4.2%
C: 1.3%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.82%
H: 0.02%
C: -0.85%
SNY | News | $47.85 1.49% 920K
|
Health Technology
|
| O: 0.17%
H: 0.0%
C: 0.0%
OMER | $3.16 2.6% 89K
|
Health Technology
|
| O: 0.19%
H: 2.22%
C: 1.76%
IMGN | News | $31.23 0.03% 49M
|
Health Technology
|
| O: 0.58%
H: 2.57%
C: 0.26%
companies pipeline trial
Lyndra Therapeutics Doses First Clinical Trial Participant in Pivotal Study of Oral Weekly Risperidone (LYN-005) for Schizophrenia and Schizoaffective Disorder
Published: 2023-05-09 (Crawled : 15:00) - biospace.com/
FNCTF | News | $11.16 130
|
Communications
|
| O: -0.66%
H: 0.0%
C: 0.0%
GILD | $67.25 0.45% 2M
|
Health Technology
|
| O: -0.36%
H: 1.23%
C: 0.63%
lyn-005 schizophrenia trial therapeutics study
The Simon Law Group and The Trial Lab Secure Historic Verdict of $161 Million in Soulliere v. Suzuki Motor of America, Inc. Motorcycle Accident Case
Published: 2023-05-05 (Crawled : 16:00) - prnewswire.com
SZKMY | $45.67 10K
|
Manufacturing
|
| O: 0.98%
H: 0.88%
C: 0.63%
group trial simon
Nuvalent to Present ALKOVE-1 Trial in Progress Poster for NVL-655 at the European Lung Cancer Congress (ELCC 2023)
Published: 2023-03-23 (Crawled : 11:00) - prnewswire.com
NUVL | $67.545 4.74% 160K
|
|
| O: 1.54%
H: 0.88%
C: -1.52%
nvl-655 lung cancer trial
BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting
Published: 2023-03-07 (Crawled : 21:00) - globenewswire.com
FNCTF | News | $11.16 130
|
Communications
| Email alert
Add to watchlist
BICX | $0.75 4.2K
|
Health Care and Social Assistan...
| Email alert
Add to watchlist
meeting trial positive results phase 1
Merck Provides Update on Phase 3 MOVe-AHEAD Trial Evaluating LAGEVRIO™ (molnupiravir) for Post-exposure Prophylaxis for Prevention of COVID-19
Published: 2023-02-21 (Crawled : 22:00) - biospace.com/
MRK | $126.99 0.04% 3.1M
|
Health Technology
|
| O: -0.57%
H: 0.9%
C: 0.16%
covid-19 trial update
AstraZeneca and Merck present final results of key secondary overall survival endpoint from Phase III PROpel trial at ASCO GU Cancers Symposium
Published: 2023-02-16 (Crawled : 16:00) - biospace.com/
FNCTF | News | $11.16 130
|
Communications
|
| O: 7.92%
H: 0.0%
C: 0.0%
propel symposium trial asco results
Gainers vs Losers
| 87% | 13% |
Top 10 Gainers
MTTR | News M | $4.64 166.67% 18M
|
AGBA | $2.61 108.8% 41M
|
Finance
CZOO | $9.32 86.77% 18M
|
EDBL | News | $6.7 78.19% 1.7M
|
OPRT | News | $3.37 49.78% 8.9M
|
Finance
MTC | $2.14 37.18% 4.9M
|
Technology Services
VNRX | $0.8 33.33% 2.9M
|
Health Technology
MLEC | $1.79 27.86% 2.6M
|
n/a
PALI | $6.29 27.59% 22M
|
Manufacturing
MCRB | $0.7902 26.51% 6.9M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.